Drug Profile

Tanimilast - Chiesi Farmaceutici

Alternative Names: CHF 6001 NEXThaler DPI; CHF 6001 NEXThaler^®; CHF-6001; CHF6001 DPI

Latest Information Update: 27 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chiesi Farmaceutici
Class Antiallergics; Antiasthmatics; Benzoates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyridines; Small molecules; Sulfonamides
Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Jan 2026 Chiesi Farmaceutici terminates a phase III PILLAR trial in Chronic obstructive pulmonary disease (Adjunctive treatment) in USA, Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Czech Republic, Croatia, Estonia, Germany, Hungary, Greece, Israel, South Korea, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russia, Serbia, Slovakia, Spain, Turkey, Ukraine and the United Kingdom (Inhalation) due to strategic decision by sponsor and not due to safety reasons before January 2026 (EudraCT2020-003648-97) (NCT04636814)
18 Dec 2025 Chiesi Farmaceutici terminates phase-II clinical trials in Asthma (Treatment-experienced) in Spain, South Africa, Romania, Poland, Lithuania, Latvia, South Korea, Italy, Hungary, Georgia, Germany, Czech Republic, Bulgaria, Argentina (Inhalation) due to strategic decision by sponsor (NCT06029595)
11 Aug 2025 Chiesi Farmaceutici completes a phase II trial in Asthma (In adolescents, In adults, In the elderly) in Bulgaria (Inhalation) (NCT06900816)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com